Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy [Yahoo! Finance]
ASAHI KAISEI CRP UNSP/ADR (AHKSY)
NASDAQ:AMEX Investor Relations:
asahi-kasei.co.jp/asahi/en/ir
Company Research
Source: Yahoo! Finance
Aicuris revenue expected to reach $500 million by 2030 FDA has granted Priority Review for the pritelivir New Drug Application. Prescription Drug User Fee Act (PDUFA) target date is Q4 2026 TOKYO, April 20, 2026 BUSINESS WIRE Asahi Kasei, a diversified global company, announced the successful completion of its acquisition of Aicuris Anti-infective Cures AG (Aicuris), a German-based biopharmaceutical company. This closing marks a key step in accelerating the company's efforts to build a global specialty pharmaceutical platform by expanding further into severe infectious diseases. "The completion of the Aicuris acquisition reflects the deliberate execution of our pharmaceutical strategy and strengthens our position in infectious diseases, a core area where we see sustained demand, high unmet need, and long-term growth," stated Ken Shinomiya, Head of Asahi Kasei's Healthcare Sector. "Aicuris adds a differentiated portfolio and scientific capabilities that enhance the quality of ou
Show less
Read more
Impact Snapshot
Event Time:
AHKSY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AHKSY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AHKSY alerts
High impacting ASAHI KAISEI CRP UNSP/ADR news events
Weekly update
A roundup of the hottest topics
AHKSY
News
- Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical StrategyBusiness Wire
- Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases [Yahoo! Finance]Yahoo! Finance
- Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune DiseasesBusiness Wire
- Asahi Kasei (AHKSY) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- Is It Too Late To Consider Asahi Kasei (TSE:3407) After A 73% One-Year Surge? [Yahoo! Finance]Yahoo! Finance